Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...
Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO ...
Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO: Berlin Tuesday, March 24, 2026, 13:00 Hrs [IST] The Ministry ...
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026Scheduled to present retinal vascular ...
Discover the latest breakthroughs in the fight against dry, age-related macular degeneration. Learn about the first approved ...
Meta-analysis shows obstructive sleep apnea is linked to a 45% increased risk for age-related macular degeneration.
If you have dry age-related macular degeneration, your central vision may end up blurry, distorted or dim.
Metformin use is associated with reduced odds of new-onset International Classification of Diseases (ICD) coding of neovascular age-related macular degeneration (nAMD), according to a study published ...
Chugai Pharma files regulatory application with Japanese MHLW for medical device component of the Port Delivery Platform with ranibizumab: Tokyo Friday, March 20, 2026, 11:00 Hrs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results